Scarica l'app Stockscreener
30.28
5.54%
1.59
Dopo l'orario di chiusura:
30.36
0.08
+0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$28.69
Aprire:
$28.83
Volume 24 ore:
14.69M
Relative Volume:
1.40
Capitalizzazione di mercato:
$10.71B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.4685
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+12.73%
1M Prestazione:
+11.94%
6M Prestazione:
-27.90%
1 anno Prestazione:
-74.14%
Intervallo 1D:
$28.62
$30.65
Intervallo di 1 settimana:
$26.80
$30.65
Portata 52W:
$23.15
$129.39
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
30.28 | 10.71B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
BDF Gestion Invests $783,000 in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mRNA pioneer’s stock faces pivotal moment - Investing.com
Trump administration cancels Moderna contract to fight bird flu and other viruses - Arizona Daily Star
Moderna (MRNA) Sees Bullish Trading Activity with Increased Options Volume | MRNA Stock News - GuruFocus
US Senate Democrats demand Kennedy explain canceling bird flu vaccine contract - MarketScreener
Zika Virus Therapeutics Market Size & Share | Industry Growth [2032] - SkyQuest Technology
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicine - Benzinga
Moderna (MRNA) Sees Bearish Sentiment Among Option Traders | MRNA Stock News - GuruFocus
Insurers likely to cover vaccines without ACIP recommendations - Seeking Alpha
SG Americas Securities LLC Lowers Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Rakuten Securities Inc. Has $742,000 Stock Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Experts - Benzinga
Moderna Target of Unusually High Options Trading (NASDAQ:MRNA) - MarketBeat
Moderna (NASDAQ:MRNA) Stock Price Down 3.8%Here's What Happened - MarketBeat
Transcript : Moderna, Inc.Special Call - MarketScreener
Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by Tobam - MarketBeat
Union Bancaire Privee UBP SA Reduces Position in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna | History, Innovation, Challenges, & Facts - Britannica
FDA approves Moderna’s new COVID-19 vaccine - Santa Clarita Valley Signal
FDA approves expanded use of Moderna’s RSV shot - MSN
Moderna, Inc. (MRNA) stock price, news, quote and history - Yahoo
GAMMA Investing LLC Grows Stake in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Moderna’s SWOT analysis: mrna stock faces challenges amid vaccine shifts - Investing.com
Here's Why Moderna (MRNA) Fell More Than Broader Market - sharewise
Moderna Seeks Outside Investors to Fund Select Vaccine Trials - MSN
FDA expands approval of Moderna’s RSV vaccine to some adults under age 60 - weisradio.com
FDA expands approval of Moderna's RSV vaccine to some adults under age 60 - WBAL News Radio
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains - The Hill
IBM and Moderna tout use cases for AI in total rewards - HR Brew
Moderna falls on doubts over new CDC panel's backing of RSV vaccine - Reuters
Moderna (MRNA) Faces Challenges Despite RSV Vaccine Approval - GuruFocus
Moderna wins FDA OK to widen use of RSV vaccine - BioPharma Dive
Moderna Stock Falls on CDC Panel Concerns Over RSV VaccineNews and Statistics - IndexBox
FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59 - The Boston Globe
Moderna under pressure despite RSV vaccine approval into wider age group - MSN
FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults - The Pharma Letter
Moderna (MRNA) Faces Intensified Short Selling Amid Challenges - GuruFocus
Moderna falls on fears new CDC vaccine advisory panel could cloud RSV shot prospects - TradingView
Moderna Wins Expanded Label for mRNA RSV Shot as New ACIP Members Question mRNA Technology - BioSpace
Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults - Yahoo Finance
Moderna's RSV shot gets US nod for use in younger adults - pharmaphorum
Moderna (MRNA) Gains FDA Approval for Expanded RSV Vaccine Use - GuruFocus
FDA expands Moderna's RSV vaccine approval to at-risk adults (MRNA:NASDAQ) - Seeking Alpha
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Up - Benzinga
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease - Knoxville News Sentinel
Moderna Gets FDA Approval for mRESVIA in Adults Aged 18-59 at Increased Risk for RSV Disease - marketscreener.com
Moderna (MRNA) Receives FDA Nod for RSV Vaccine Extended Use | M - GuruFocus
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):